Monotherapy VersusMetformin in Type 2 Diabetes in a Randomized Controlled Trial ( AWARD-3 )

@inproceedings{Umpierrez2014MonotherapyVI,
  title={Monotherapy VersusMetformin in Type 2 Diabetes in a Randomized Controlled Trial ( AWARD-3 )},
  author={Guillermo E Umpierrez and Santiago Tof{\'e} Povedano and Federico P{\'e}rez Manghi and Linda Shurzinske and Valeria Pechtner},
  year={2014}
}
RESULTS At 26 weeks, changes from baseline HbA1c (least squares [LS] mean 6 SE) were: dulaglutide 1.5mg,20.786 0.06% (28.56 0.70mmol/mol); dulaglutide 0.75mg, 20.716 0.06% (27.86 0.70mmol/mol); andmetformin,20.566 0.06% (26.16 0.70 mmol/mol). Dulaglutide 1.5 and 0.75 mg were superior to metformin (LS mean difference): 20.22% (22.4 mmol/mol) and 20.15% (21.6 mmol/mol) (one-sided P < 0.025, both comparisons), respectively. Greater percentages reached HbA1c targets <7.0% (<53 mmol/mol) and £6.5… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
61 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…